Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression

Compared with calcineurin inhibitor–based immunosuppression, belatacept (BELA)-based treatment has been associated with better renal function but higher acute rejection rates. This phase 2 study (NCT02137239) compared the antirejection efficacy of BELA plus everolimus (EVL) with tacrolimus (TAC) plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Peddi, V. Ram, Marder, Bradley, Gaite, Luis, Oberholzer, Jose, Goldberg, Ryan, Pearson, Thomas, Yang, Harold, Allamassey, Lisa, Polinsky, Martin, Formica, Richard N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820789/
https://www.ncbi.nlm.nih.gov/pubmed/36700062
http://dx.doi.org/10.1097/TXD.0000000000001419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820789/
https://www.ncbi.nlm.nih.gov/pubmed/36700062
http://dx.doi.org/10.1097/TXD.0000000000001419

Ejemplares similares